JPRN-UMIN000029005RecruitingPhase 1
VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors - VEGFR 1/2 Peptide Vaccine for Recurrent, Progressive and Refractory Brain Tumors
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 12years-old to 79years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Uncontrollable severe infectious diseases. 2) Serious concomitant diseases 3) Adverse event of NCI-CTC grade 3 or 4. 4) Unable to take anything orally over 24 hours. 5) Active multiple cancers. 6) Myeloproliferative diseases such as MDS and CML. 7) After allogeneic hematopoietic stem cell transplantation. 8) Active autoimmune diseases. 9) Severe drug allergy 10) Necessity for administration of steroid or immunosuppressive drugs. 11) Pregnancy or lactation. Patients hope pregnancy 12) Psychiatric disorders. 13) Unhealed injury. 14) Judged as inappropriate for this study by doctors.
Investigators
Similar Trials
Recruiting
Phase 1
VEGFR 1/2 Peptide Vaccine for Recurrent, Progressive and Refractory Brain TumorsJPRN-jRCTs031180162Toda Masahiro20
Completed
Not Applicable
Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapycolorectal cancerJPRN-UMIN000002856Devision of Clinical Oncology, Tohoku University Hospital15
Active, not recruiting
Phase 1
Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?EUCTR2011-002667-14-CZInstitute of Hematology and Blood Transfusion50
Completed
Phase 1
Phase I study of peptide vaccination in patients with refractory gastrointestinal cancerGastrointestinal cancerJPRN-UMIN000008820ational Cancer Center Hospital18
Unknown
Phase 1
Cancer vaccination therapy by using VEGFRs-targeted peptides in the patients who have received trans-arterial chemo-embolization (TACE) against hepatocellular carcinoma -A randomized double blind studyhepatocellular carcinomaJPRN-UMIN000001731Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University30